Date: October 1, 2023
BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents.
Date: October 1, 2023
Pomalidomide plus bortezomib and dexamethasone confers a larger progression-free survival benefit than bortezombib plus dexamethasone among patients with relapsed/refractory multiple myeloma in the phase 3 OPTIMISMM trial.
Date: October 1, 2023
For large cell lymphomas, physicians typically use CT and positron emission tomography-computed tomography scans to look for signs of minimum residual disease when treatment is completed.
Date: October 1, 2023
The FDA has granted an orphan drug designation to alisertib (MLN8237) for the treatment of patients with extensive-stage small cell lung cancer.
Date: September 30, 2023
Positive response and preliminary evidence of longer progression-free survival was observed with a venetoclax-based triplet therapy vs a doublet, in a phase. 2 study.
Date: September 30, 2023
The biologic license application for odronextamab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma is based on data from the phase 1 ELM- 1 and phase 2 ELM-2 studies.
Date: September 30, 2023
The observed benefits of ciltacabtagene autoleucel in patients with multiple myeloma and poor prognostic features are consistent with the overall the population of CARTITUDE-4.
Date: September 30, 2023
Neeraj Agarwal, MD, states that he is optimistic about the development of new treatment options including immunotherapies, CAR T-cell therapies, and antibody-drug conjugates for metastatic prostate cancer.
Date: September 30, 2023
Jiye Liu, PhD, discusses epigenetic regulation of CD38/CD48 in multiple myeloma.
Date: September 30, 2023
NXC-201 has demonstrated safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.
Date: September 30, 2023
Leo Rasche, MD, discusses BCMA and GPRC5D loss after bispecific antibody therapy in multiple myeloma.
Date: September 30, 2023
In the phase 3 CARTITUDE-4 trial, ciltacabtagene autoleucel was shown to be effective when used in patients with multiple myeloma exhibiting poor prognostic features.
Date: September 30, 2023
The addition of venetoclax to carfilzomib and dexamethasone increased response rates compared with carfilzomib plus dexamethasone alone in patients with t(11:14)-positive relapsed/refractory multiple myeloma.
Date: September 30, 2023
The novel anti-BCMA CAR T-cell therapy NXC-201 displayed safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.
Date: September 30, 2023
In an interview with Targeted Oncology, Justin Taylor, MD, discussed early research on NX-2127, a BTK degrader being evaluated for the treatment of chronic lymphocytic leukemia.
Date: September 30, 2023
At separate live virtual events, Brea C. Lipe, MD, and Amandeep Godara, MD, MBBS, discussed options for the same elderly patient with multiple myeloma who is not able to receive a transplant.
Date: September 30, 2023
Patients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class exposure, experienced significant progression-free survival benefit with ciltacabtagene autoleucel.
Date: September 29, 2023
The EZH2 inhibitor tazemetostat may mimic the role of the KDM6A gene in upregulating CD38 and CD48 expression, suggesting that this agent could restore responses to daratumamab in patients with multiple myeloma, according to a presentation at the 20th International Myeloma Society Annual Meeting.
Date: September 29, 2023
IberVd showed high efficacy with deep, ongoing responses among older patients with transplant-ineligible, newly diagnosed multiple myeloma.
Date: September 29, 2023
Mitchell Machtay, MD, discusses the association between the levels of circulating immune biomarkers prior to immunotherapy and survival outcomes in patients with stage III non-small cell lung cancer.
Date: September 29, 2023
Biagio Ricciuti, MD, discusses the association between PD-L1 expression levels and long-term survival with anti–PD-L1 monotherapy in patients with advanced non–small cell lung cancer.
Date: September 29, 2023
The combination of iberdomide plus bortezomib and dexamethasone produced deep responses with a manageable toxicity profile in patients with transplant-ineligible, newly diagnosed multiple myeloma, according to data from the phase 1/2 CC-220-MM-001 trial presented at the 2023 International Myeloma Society Annual Meeting.
Date: September 29, 2023
Damon R. Reed, MD, discusses the genetic differences that distinguish Ewing sarcoma from osteosarcoma, as well as unmet needs in patients with these diseases.
Date: September 29, 2023
Researchers identified KDM6A’s role in CD38 regulation and found that an EZH2 inhibitor could potentially reduce resistance to an anti-CD38 antibody in multiple myeloma cells.
Date: September 29, 2023
Ana Velázquez Mañana, MD, discusses findings from a study determining survivorship care needs in low-income, older patients with lung cancer.
Date: September 29, 2023
Treatment with teclistamab led to responses in patients with relapsed/refractory multiple myeloma, including those previously exposed to anti-BCMA therapies.
Date: September 29, 2023
Forimtamig monotherapy generated high overall response rates and durable responses in all subgroups of patients with relapsed/refractory multiple myeloma enrolled in a phase 1a dose-escalation trial.
Date: September 29, 2023
Although response rates were lower among patients given previous anti-BCMA therapy, teclistamab shows promise for all patients with relapsed/refractory multiple myeloma.
Date: September 29, 2023
Jeremy C. Jones, MD, discusses the applications of circulating tumor DNA testing in colorectal cancer.
Date: September 29, 2023
At a median duration of response of 12.2 months, the objective response rates with forimtamig across all dose levels was 66.7% with a very good partial response rate of 54.2%, according to data from a phase 1a dose-escalation trial.
Date: September 29, 2023
Lubna Chaudhary, MD, MS, discusses the ongoing investigation and utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and compared this agent’s efficacy with that of trastuzumab emtansine.